LeonaBio Inc (LONA)
LeonaBio, Inc. is a clinical-stage biopharmaceutical company listed on the NASDAQ under the ticker LONA. The company focuses on developing small-molecule therapies aimed at restoring neuronal health and slowing neurodegeneration. Its pipeline includes ATH-1105, being studied in a phase 1 clinical trial for amyotrophic lateral sclerosis, and ATH-1020, which is also in phase 1 development for neurodegenerative diseases. LeonaBio also has earlier-stage compounds in preclinical development. The company was previously known as Athira Pharma, Inc. and adopted its current name in January 2026. Incorporated in 2011, LeonaBio is headquartered in Bothell, Washington.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-LONA
|
$8.22
|
4.8% Upside
|
Fair
|
$18
|
129.6% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 17, 2026
|
-0.6x
|
1.5x
|
—
|
71.109 M
|
6.657 M
|
1.0%
|
59.8%
|
-9.7
|
—
|
40.2%
|
